Forge is a gene therapy development engine, focused on enabling access to life changing gene therapies and helping bring them from idea into reality.
Forge's gene therapy provides manufacturing and development services to other companies while working on its own pipeline.
Forge Biologics was founded in 2020 by Tim Miller, Jaysson Eicholtz and Erandi De Silva. The company is headquartered in Columbus, Ohio.
Forge offers end-to-end manufacturing services, including research and toxicology grade AAV production, to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing.
Forge is also working to advance a proprietary pipeline of novel gene therapies, including its lead program FBX-101 for the treatment of patients with Krabbe disease, a first-in-human gene therapy utilizing an AAV to deliver a functioning copy of the GALC gene intravenously to cells in the central nervous system (CNS) and peripheral organs.
Forge is backed by RA Capital Management, Perceptive Xontogeny Venture Fund, Drive Capital, Surveyor Capital, Octagon Capital and others. The company raised $120M in Series B round on Apr 29, 2021. This brings Forge's total funding to $160M to date.